Patents by Inventor Sebastian Amigorena
Sebastian Amigorena has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101616Abstract: A chimeric antigen receptor including: a binding domain, the full DAP 10 protein, the full DAP 12 protein, or a functional variant thereof, and a hook binding domain. Also, a vector system comprising one or more vector including: a nucleic acid comprising a nucleic acid sequence encoding a chimeric antigen receptor and optionally a nucleic acid encoding a hook fusion protein, preferably having a streptavidin core; wherein the nucleic acids are located on the same or on different vectors. Further, a lentiviral vector particles system, host cell and kit including the nucleic acids or vector system, and their use as a medicament, notably for immunotherapy.Type: ApplicationFiled: November 21, 2023Publication date: March 28, 2024Applicants: INSTITUT CURIE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Franck Perez, Zelia Gouveia, Sebastian Amigorena, Gaelle Boncompain
-
Publication number: 20240082372Abstract: The present disclosure relates to a method for selecting a tumor neoantigenic peptide wherein said method comprises: —a step of identifying, among mRNA sequences from cancer cells of a subject, a fusion transcript sequence comprising a transposable element (TE) sequence and an exonic sequence, and including an open reading frame (ORF), and —a step of selecting a tumor neoantigenic peptide of at least 8 amino acids, encoded by a part of said ORF of the fusion transcript sequence, wherein said ORF overlaps the junction between the TE and the exonic sequence, is pure TE and/or is non-canonical, and wherein said tumor neoantigenic peptide binds to at least one Major Histocompatibility Complex (MHC) molecule of said subject. The present disclosure also relates to tumor neoantigenic peptide obtained according to the present method, vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.Type: ApplicationFiled: September 2, 2020Publication date: March 14, 2024Inventors: Sebastian AMIGORENA, Marianne BURBAGE, Alexandre HOUY, Marc-Henri STERN, Joshua WATERFALL, Benjamin SADACCA, Antonela MERLOTTI IPPOLITO, Yago ARRIBAS DE SANDOVAL
-
Publication number: 20230322952Abstract: The invention provides a multispecific molecule capable of simultaneous binding to a Mucosal Associated Invariant T (MAIT) cell and a tumor cell, which multispecific molecule comprises at least one domain that specifically binds a V?7.2 T cell receptor (TCR) and at least one domain that specifically binds a tumor associated antigen (TAA).Type: ApplicationFiled: January 8, 2021Publication date: October 12, 2023Inventors: OLIVIER LANTZ, SEBASTIAN AMIGORENA, MICHAEL SAITAKIS, MAUDE GUILLOT-DELOST, EUGENE ZHUKOVSKY, PIERRE-EMMANUEL GERARD, MUSTAPHA FAROUDI
-
Publication number: 20230303974Abstract: The present invention relates to an engineered immune cell defective for SOCS1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of SOCS1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: ApplicationFiled: July 30, 2021Publication date: September 28, 2023Applicants: Institut Curie, Institut National de la Santé et de la Recherche MédicaleInventors: Laurie Menger, Silvia Menegatti, Sebastian Amigorena
-
Publication number: 20230201264Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: ApplicationFiled: March 2, 2023Publication date: June 29, 2023Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Christel GOUDOT, Luigia PACE, Genevieve ALMOUZNI
-
Patent number: 11622978Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: GrantFiled: January 20, 2020Date of Patent: April 11, 2023Assignees: INSTITUT CURIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Sebastian Amigorena, Eliane Piaggio, Christel Goudot, Luigia Pace, Genevieve Almouzni, Leticia Niborski
-
Publication number: 20220331332Abstract: The present invention relates to methods and pharmaceutical composition for the treatment of T-helper type 2 (Th2)-mediated diseases. More particularly, the present invention relates to an inhibitor of the Suv39h1-HP1a silencing pathway for use in the treatment of a T-helper type 2 (Th2)-mediated disease, in particular allergic asthma.Type: ApplicationFiled: May 6, 2022Publication date: October 20, 2022Inventors: Sebastian AMIGORENA, Rhys ALLAN, Heidi SCHREIBER, Elina ZUEVA, Genevieve ALMOUSNI
-
Publication number: 20220251572Abstract: The present invention relates to an improved immune cell expressing an antigen-specific receptor such as a CAR or TCR, in which SUV39H1 is inactivated, optionally combined with disruption of the TRAC locus and/or deletion of one or more ITAMs. The invention also provides compositions comprising such cells, methods of producing such cells, and uses of such cells in adoptive cell therapy, e.g. in cancer or inflammatory diseases.Type: ApplicationFiled: July 23, 2020Publication date: August 11, 2022Inventors: Sebastian AMIGORENA, Michael SAITAKIS, Sheila LOPEZ-COBO, Jaime Rodrigo FUENTEALBA
-
Publication number: 20220193198Abstract: The invention relates to Interleukin-2 (IL-2) variants for the prevention or treatment of immune disorders, including with no limitations allergic, autoimmune, chronic or acute inflammatory and infectious diseases; graft-versus-host disease; graft rejection and cancer. The invention also relates to the use of said IL-2 variants for the screening of anti-IL-2 antibodies with pro-T-effector or pro-T-regulatory cell activity.Type: ApplicationFiled: March 27, 2020Publication date: June 23, 2022Applicants: Institut Curie, Institut National de la Sante et de la Recherche Medicale, Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Eliane PIAGGIO, Sebastian AMIGORENA, Pamela CAUDANA, Felix REY, Gleyder ROMAN-SOSA, Pablo GUARDADO-CALVO
-
Patent number: 11285176Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: GrantFiled: October 21, 2021Date of Patent: March 29, 2022Assignees: INSTITUT CURIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRSInventors: Sebastian Amigorena, Eliane Piaggio, Christel Goudot, Luigia Pace, Genevieve Almouzni, Leticia Niborski
-
Publication number: 20220040235Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: ApplicationFiled: October 21, 2021Publication date: February 10, 2022Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Christel GOUDOT, Luigia PACE, Genevieve ALMOUZNI
-
Patent number: 10968281Abstract: The present invention provides a new anti-LSP1 (Leukocyte specific protein 1) antibody. This new antibody allows the specific staining of inflammatory dendritic cells and can be used in diagnosis methods or as a medicament when conjugated to a drug.Type: GrantFiled: October 13, 2017Date of Patent: April 6, 2021Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALEInventors: Elodie Segura, Sebastian Amigorena, Franck Perez, Sandrine Moutel
-
Publication number: 20210060158Abstract: The present invention relates to an AhR agonist for use in combination with at least one immune checkpoint modulator in the treatment of cancer. The present invention also encompasses product containing an AhR agonist and at least one immune checkpoint modulator as defined in any one of the preceding, claims, as a combined preparation for simultaneous, separate or sequential use in the treatment of cancer.Type: ApplicationFiled: September 19, 2018Publication date: March 4, 2021Inventors: Sebastian Amigorena, Elodie Segura
-
Publication number: 20210009653Abstract: The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.Type: ApplicationFiled: July 17, 2020Publication date: January 14, 2021Inventors: Sophie AGAUGUE, Lorenzo TIBALDI, Klervi EVEN-DESRUMAUX, Dmitry TRUBETSKOY, Franck PEREZ, Sebastian AMIGORENA, Cécile BAUCHE
-
Publication number: 20200405853Abstract: The present invention relates to an inhibitor of H3K9 histone methyl transferase SETDB1 for use in combination with at least one immune checkpoint modulator in the treatment of cancer.Type: ApplicationFiled: March 6, 2019Publication date: December 31, 2020Inventors: Sebastian AMIGORENA, Marianne BURBAGE, Derek ROOKHUIZEN
-
Publication number: 20200331975Abstract: The present invention relates to a chimeric antigen receptor comprising: a binding domain, the full DAP 10 protein, the full DAP 12 protein, or a functional variant thereof, anda hook binding domain.The present invention also relates to a vector system comprising one or more vector comprising: a nucleic acid comprising a nucleic acid sequence encoding a chimeric antigen receptor and optionally a nucleic acid encoding a hook fusion protein, preferably comprising a streptavidin core; wherein said nucleic acids are located on the same or on different vectors; The invention also encompasses lentiviral vector particles system, host cell and kit comprising said nucleic acids or vector system. The invention also relates to lentiviral vector particles system, host cell and kit as herein disclosed for their use as a medicament, notably for immunotherapy.Type: ApplicationFiled: October 22, 2018Publication date: October 22, 2020Inventors: Franck Perez, Zelia Gouveia, Sebastian Amigorena, Gaelle Boncompain
-
Patent number: 10752668Abstract: The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.Type: GrantFiled: July 24, 2015Date of Patent: August 25, 2020Assignees: Theravectys, Institut Curie, Centre National de la Recherche Scientifique, Sorbonne Universite, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Sophie Agaugue, Lorenzo Tibaldi, Klervi Even-Desrumaux, Dmitry Trubetskoy, Franck Perez, Sebastian Amigorena, Cécile Bauche
-
Publication number: 20200171090Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: ApplicationFiled: January 20, 2020Publication date: June 4, 2020Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Christel GOUDOT, Luigia PACE, Genevieve ALMOUZNI
-
Publication number: 20200157225Abstract: The present invention relates to an inhibitor of H3K9 histone methyl transferase SUV39H1 for use in combination with at least one immune checkpoint modulator in the treatment of cancer.Type: ApplicationFiled: January 27, 2020Publication date: May 21, 2020Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Leticia NIBORSKI
-
Publication number: 20200147099Abstract: The present invention relates to an inhibitor of H3K9 histone methyl transferase SUV39H1 for use in combination with at least one immune checkpoint modulator in the treatment of cancer.Type: ApplicationFiled: June 20, 2018Publication date: May 14, 2020Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Leticia NIBORSKI